scholarly journals Prevalence of chronic liver disease among young/middle-aged adults in Northern Italy: role of hepatitis B and hepatitis C virus infection by age, sex, ethnicity

Heliyon ◽  
2019 ◽  
Vol 5 (7) ◽  
pp. e02114
Author(s):  
Ugo Fedeli ◽  
Francesco Avossa ◽  
Eliana Ferroni ◽  
Angela De Paoli ◽  
Francesco Donato ◽  
...  
2004 ◽  
Vol 41 (3) ◽  
pp. 180-184 ◽  
Author(s):  
Angelo Alves de Mattos ◽  
Eliana Buksztejn Gomes ◽  
Cristiane Valle Tovo ◽  
Cláudio Osmar Pereira Alexandre ◽  
José Oscar dos Reis Remião

BACKGROUND: Considering the immunosuppression of patients with chronic liver disease, their response to vaccination is discussed in literature. AIMS: To evaluate the response of hepatitis B vaccine in patients with chronic hepatitis C virus infection. METHODS: This is a prospective study in which 85 patients with chronic hepatitis C virus infection (46.8 ± 9.4 years, 44.7% males) and 46 healthy adults (36.7 ± 11.1 years; 39.1% males) were evaluated. Confirmation of hepatitis C virus was obtained by the technique of polymerase chain reaction. Viral load was determined by the branched DNA method in 74 patients, and genotype was determined by sequencing in 73 patients. All patients and healthy adults received three doses of Engerix B® vaccine IM (at 0, 30 and 180 days). Serological responses to the vaccine were divided into three categories: seroprotection, when anti-HBs was >100 mUI/mL; seroconversion, when anti-HBs was 10-99 mUI/mL, and non-reagent, when anti-HBs was <10 mUI/mL. RESULTS: The response of hepatitis B vaccine as determined 1 month following dose 3 was seroprotection in 37.7%, seroconversion in 17.6% and non-reagent in 44.7% among patients and 84.8%, 13.0%, 2.2%, respectively in healthy adults. The number of non-reagent responses was significantly higher among those patients with chronic liver disease. Sixty-five patients with chronic hepatitis were compared to 20 compensated cirrhotic patients in concern to the response to vaccine, but no difference was found. The response to vaccine in patients with genotypes 2 or 3 (n = 40) was better than in those with genotype 1 (n = 33). Response was not related to serum HCV-RNA concentration. CONCLUSION: The number of non-responders was higher in patients with chronic hepatitis C virus infection, irrespective of histological status and viral load. It is suggested that such patients should receive a double dose of vaccine, particularly the ones with genotype 1.


2002 ◽  
Vol 36 ◽  
pp. 229
Author(s):  
Cristiane Both ◽  
Eliana Gomes ◽  
Claudio Alexandre ◽  
Jose Remiao ◽  
Gabriela Coral ◽  
...  

1993 ◽  
Vol 25 (5) ◽  
pp. 559-564 ◽  
Author(s):  
Khalif Bile ◽  
Cadigia Aden ◽  
Heléne Norder ◽  
Lars Magnius ◽  
Greger Lindberg ◽  
...  

2008 ◽  
Vol 12 (5) ◽  
pp. 513-518 ◽  
Author(s):  
Shanmugam Saravanan ◽  
Vijayakumar Velu ◽  
Nagalingeswaran Kumarasamy ◽  
Esaki Muthu Shankar ◽  
Subhadra Nandakumar ◽  
...  

Infection ◽  
1994 ◽  
Vol 22 (3) ◽  
pp. 183-186 ◽  
Author(s):  
M. Coltorti ◽  
Nicola Caporaso ◽  
Filomena Morisco ◽  
Rosalba Suozzo ◽  
M. Romano ◽  
...  

Author(s):  
João Manuel Silva ◽  
Mário Jorge Silva ◽  
Filipe Calinas ◽  
Paulo Jorge Nogueira

<b><i>Introduction:</i></b> Liver cirrhosis is a prevalent disease in Portugal. Recent changes in alcohol consumption, as well as the wide use of direct-acting antivirals for hepatitis C since 2015, may be contributing to changes in the national burden of liver cirrhosis in the last few years. <b><i>Objectives:</i></b> We aim to characterize the burden of cirrhosis in Portugal between 2010 and 2017. <b><i>Patients and Methods:</i></b> We analyzed all hospital admission episodes due to cirrhosis in Portugal Mainland between 2010 and 2017, registered in the national Diagnosis-Related Group database, according to etiology of cirrhosis. We also analyzed data on mortality and potential years of life lost from liver cirrhosis and chronic liver disease, retrieved from Statistics Portugal (National Institute for Statistics). <b><i>Results:</i></b> Between 2010 and 2017, a total of 51,438 admissions for liver cirrhosis occurred in Portugal. The annual number of admissions decreased (<i>p</i> = 0.044) during the analyzed period. The most frequent cause of cirrhosis was alcoholic liver disease, present in 78.9% of all admissions (<i>n</i> = 40,595), followed by chronic hepatitis C virus infection, present in 11.3% (<i>n</i> = 5,823). A male predominance was identified in the admissions for every analyzed cause of cirrhosis. Annual admissions for alcoholic cirrhosis remained stable (<i>p</i> = 0.075) during the 8-year period. The same stable tendency was observed in the number of admissions for cirrhosis caused by hepatitis C virus (<i>p</i> = 0.861) and alcohol plus hepatitis C virus infection (<i>p</i> = 0.082), although these admissions for hepatitis C-related cirrhosis increased until 2014–2015 and steadily decreased thereafter. Annual deaths due to liver cirrhosis and chronic liver disease decreased from 1,357 in 2010 to 1,038 in 2017 (<i>p</i> = 0.002). The number of potential years of life lost decreased as well in the period (<i>p</i> = 0.001). <b><i>Conclusion:</i></b> The burden of cirrhosis, evaluated by hospital admissions, mortality, and potential years of life lost, decreased in Portugal between 2010 and 2017.


Sign in / Sign up

Export Citation Format

Share Document